An Open-Label, Investigator-Blinded, Randomized, Parellel Group Study to Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA 325 Versus Enteric-Coated Aspirin.

Trial Profile

An Open-Label, Investigator-Blinded, Randomized, Parellel Group Study to Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA 325 Versus Enteric-Coated Aspirin.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2010

At a glance

  • Drugs Aspirin; Aspirin/omeprazole
  • Indications NSAID-induced gastrointestinal damage
  • Focus Adverse reactions
  • Sponsors POZEN
  • Most Recent Events

    • 07 May 2010 Results were presented at the 29th Annual Scientific Meeting of the American Pain Society (APS), according to a POZEN media release.
    • 09 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top